OVERSHINE CELLARS, LLC – Trademark Portfolio

Entity Type: 16

OVERSHINE CELLARS, LLC holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 33 (Wine & Spirits) — 12 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 2 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include REEVE, POIZIN, IDLEWILD, BLOODROOT, and LIBERTINE. The owner is based in HEALDSBURG, CA.

2201 WESTSIDE ROAD

HEALDSBURG, CA 95448

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

OVERSHINE CELLARS, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

33
Wine & Spirits (12 filings)

Alcoholic beverages (except beers)

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does OVERSHINE CELLARS, LLC have?

OVERSHINE CELLARS, LLC has 13 U.S. trademarks filed with the USPTO. Of these, 8 registered, 1 abandoned, 4 cancelled.

What trademark classes does OVERSHINE CELLARS, LLC file in?

OVERSHINE CELLARS, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 33 (Wine & Spirits), Class 41 (Education & Entertainment). Class 33 covers alcoholic beverages (except beers).

What are OVERSHINE CELLARS, LLC's most well-known trademarks?

OVERSHINE CELLARS, LLC's registered trademark portfolio includes well-known marks such as REEVE, POIZIN, IDLEWILD, BLOODROOT, and LIBERTINE. These are among 8 currently registered trademarks in the portfolio.

What is OVERSHINE CELLARS, LLC's trademark registration success rate?

OVERSHINE CELLARS, LLC has a 62% trademark registration rate, with 8 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.